Thymosin alpha-1 FAQ: the top questions answered
The short version: thymosin alpha-1 is an immune-signaling peptide with decades of international use. It is not FDA-approved in the U.S. Here are the questions clinicians hear most.
TL;DR
- Thymosin alpha-1 is a 28-amino-acid peptide that signals immune cells.
- It is approved in over 30 countries as Zadaxin but not in the U.S.
- Compounded Tα1 is accessed in the U.S. through 503A pharmacies and is not FDA-approved.
What it is
Thymosin alpha-1 is a small protein originally isolated from the thymus gland (in plain English: the small organ in the upper chest where T-cells, the immune system's specialized fighters, learn what to attack and what to leave alone). The synthetic version is called thymalfasin. It is sold internationally as Zadaxin.
How it works
Think of the immune system as airport security. Dendritic cells are the screeners who decide what is suspicious. Thymosin alpha-1 is a quiet voice in the screeners' ear, helping them notice the right things and ignore the rest. It binds toll-like receptors on dendritic cells, which then help T-cells mature and respond accurately to threats (Garaci et al., Ann NY Acad Sci, 2015).
Who asks about it
People come to thymosin alpha-1 after reading about it in immunology contexts — hepatitis B, cancer immunotherapy support, vaccine response. Most are not facing those specific conditions; they are asking whether immune support has a real evidence base or is marketing language.
What the research says
The strongest data is in chronic hepatitis B, where Zadaxin showed virologic response in subsets of patients in randomized trials. Smaller trials have studied it in sepsis, vaccine response, and oncology adjuvant settings. A 2018 review found about 1 in 4 sepsis patients had improved survival in pooled analyses, though the field still considers the evidence preliminary (Liu et al., Front Immunol, 2018).
What to know before considering it
Side effects in published trials are mild and uncommon. Injection-site reactions, fatigue, or flushing occur in fewer than 1 in 10 users. People on immunosuppressive therapy, with autoimmune disease, or in active organ transplant should consult their treating physician before considering it. Any compounded peptide access requires a licensed clinician.
The Halftime POV
Thymosin alpha-1 has more international approval and trial history than most compounded peptides. Outside its specific approved indications, the data is suggestive rather than definitive — and that distinction is the right way to talk about it.
Related reading:
- Thymosin alpha-1: what this immune peptide is
- Thymosin alpha-1 research: where it has been studied
- Thymosin alpha-1 side effects and contraindications
FAQ
Q: What is thymosin alpha-1? A: Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from the thymus gland. It signals the immune system, particularly T-cell development and dendritic-cell function. It is FDA-approved internationally as Zadaxin for hepatitis B and as a vaccine adjuvant.
Q: How does thymosin alpha-1 work? A: Thymosin alpha-1 binds toll-like receptors on dendritic cells. That signal helps T-cells mature and respond to threats. The compound modulates immune balance rather than turning the immune system on or off.
Q: Is thymosin alpha-1 FDA-approved? A: No. Zadaxin (thymalfasin) is approved in over 30 countries for hepatitis B and as a vaccine adjuvant, but it is not FDA-approved in the United States. The compounded version is not FDA-approved either and is accessed only through state-licensed 503A compounding pharmacies.
Q: What are common thymosin alpha-1 side effects? A: In published trials, side effects are uncommon and mild — injection-site reactions, transient flushing, and occasional fatigue are most often reported. Serious adverse events were rare across the hepatitis B and vaccine-adjuvant programs.
Q: Who prescribes thymosin alpha-1? A: Licensed clinicians — typically infectious disease, immunology, or integrative medicine physicians — evaluate the indication and prescribe. It is not a self-directed therapy.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
Frequently asked questions
What is thymosin alpha-1?
Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from the thymus gland. It signals the immune system, particularly T-cell development and dendritic-cell function. It is FDA-approved internationally as Zadaxin for hepatitis B and as a vaccine adjuvant.
How does thymosin alpha-1 work?
Thymosin alpha-1 binds toll-like receptors on dendritic cells. That signal helps T-cells mature and respond to threats. The compound modulates immune balance rather than turning the immune system on or off.
Is thymosin alpha-1 FDA-approved?
No. Zadaxin (thymalfasin) is approved in over 30 countries for hepatitis B and as a vaccine adjuvant, but it is not FDA-approved in the United States. The compounded version is not FDA-approved either and is accessed only through state-licensed 503A compounding pharmacies.
What are common thymosin alpha-1 side effects?
In published trials, side effects are uncommon and mild — injection-site reactions, transient flushing, and occasional fatigue are most often reported. Serious adverse events were rare across the chronic hepatitis B and vaccine-adjuvant programs.
Who prescribes thymosin alpha-1?
Licensed clinicians — typically infectious disease, immunology, or integrative medicine physicians — evaluate the indication and prescribe. It is not a self-directed therapy.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.